Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pathway Genomics Launches Hereditary Colorectal Cancer Genetic Test

Published: Thursday, February 20, 2014
Last Updated: Wednesday, February 19, 2014
Bookmark and Share
Test uses NGS technology to identify gene alterations or mutations.

Pathway Genomics Corporation has announced the launch of Hereditary Colorectal Cancer DNA InsightSM, the company’s premier hereditary cancer genetic test.

Based on a simple saliva sample, the test uses next-generation sequencing (NGS) technology to identify gene alterations or mutations that increase a patient’s risk of developing certain types of cancer.

“We are committed to providing valuable tools to help physicians further improve the quality of health care,” said David Becker, Ph.D., Pathway Genomics’ chief scientific officer. “Our new hereditary colorectal cancer genetic test is part of this commitment as it empowers physicians by providing useful information about cancer risk.”

The American Cancer Society estimates 140,000 colorectal cancer cases in the U.S. in 2013. Additionally, current research data shows, on average, one in 20 people develop colorectal cancer. People with a first-degree relative with colon cancer can have two to three times the risk of developing the disease.

“Colorectal cancer is the second-leading cause of cancer-related deaths in the United States,” said Linda Wasserman, M.D., Ph.D., Pathway Genomics’ laboratory director and former director of the Clinical Cancer Genetics Care Unit at UC San Diego Moores Cancer Center. “The genetic mutations that we test for can increase a patient’s lifetime risk for the development of colorectal cancer by as much as 50 to 80 percent.”

The Hereditary Colorectal Cancer DNA Insight genetic test scans a patient’s genome for a number of conditions related to colorectal cancer, including Lynch syndrome, familial adenomatous polyposis, Li-Fraumeni syndrome, juvenile polyposis, MUTYH-associated polyposis, Peutz-Jeghers syndrome, hereditary diffuse gastric cancer, and PTEN-hamartoma tumor syndrome. Additionally, many of the genes tested play a role in other cancer types, which will also be reported to the clinician.

As part of its cancer test, Pathway Genomics offers a complimentary Familial Studies Program, which provides genetic testing to family members of qualified patients who are found to have genetic mutations where the risk for cancer is not fully understood - known in the field as a variant of unknown significance (VUS). The test provides information on how the patient and family members may be affected.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Susan G. Komen and Pathway Genomics Sign National Agreement
Agreement to fund community breast cancer education and outreach programs in five cities nationwide.
Wednesday, September 10, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!